Mentor Capital, Inc. - Cancer Immunotherapy Index

Mentor Capital, Inc. and CI Companies

$10M Cancer Assets
3M Basic Shares

About Mentor Capital About MNTR Summary Data Management Team Professional Support Philosophy Ethics Corporate Governance Investor's Corner (Contract) Analysts' Coverage $5/Share - Sr. Securities Analyst Cancer Imm Index Information Visit Portfolio Companies

Trading Chart

The Mentor Capital Cancer Immunotherapy Index ^©

PDF Document Click to see larger

Cancer Immunotherapy Index

* Cancer Immunotherapy Index was developed with Mike Havrilla, PhD., Editor of MikeHavRx.com, initially as a sub-set to his Cancer Diagnostic & Therapeutic Micro-Cap Index.
** 75% historic gain on Quantum Immunologics included in total which increases reported gain by 0.0005%. Private companies such as QI removed from index 2/12/2011.
*** Market Data from National Cancer Institute based on Relative Mortality in company treatment areas with market shared by all participating companies in their treatment areas.

NO INVESTMENT ADVISORY DISCLAIMER: Readers are cautioned that Mentor Capital, Inc. does not intend this Cancer Immunotherapy Index to be investment advice. The CI Index is a mathematical, information only index and has been published on a regular weekly basis since inception. The original and continuing purpose is to establish a benchmark as to how the cancer immunotherapy sector as a whole has behaved. As such, it presents historic information and does not purport nor imply any opinion or advice on the current or future value of any stock, nor account for trading costs that in practice will reduce investment gains.

Home

Changing Assets & Acquisitions

Warrant Information

Chairman's Letters

◦	Bringing It All Together To Win In The Cancer Fight (2011)
◦	Welcome To The Team Leading The Cancer Fight (2010)

Medicine, Science & The Economy

◦	Sunlight Explains Japan Radiation Risk

Press Releases

◦	Mentor Capital Acquires 50 Percent of Brighter Day Health For $5M
◦	Mentor Capital Begins its 2012 Cancer Roll-up Strategy
◦	MNTR acquires 30 Percent of European Cancer Vaccine for $4.71 Million
◦	Mentor Capital Adds to European Cancer Portfolio with AGI Biopharmaceuticals Melanoma Vaccine
◦	Mentor Capital Reports Mid-Year Profits for 2011
◦	Mentor Capital Initiates Discussions for Potential Merger
◦	Mentor Capital Seeks Funding Partners as Neutron Cancer Therapy Accelerates
◦	Cancer Immunotherapy Index Outpaces Biotechs
◦	Increased Chinese and International Visitors to Mentor Capital Site
◦	CEO Purchases an Additional 3.14% of MNTR Shares
◦	MNTR Drafts Five Cancer Funding Contracts for $40 Million
◦	MNTR Screens Cancer Companies For Investment At ASCO
◦	MNTR Acquires $5M Hadron Neutron Therapy Interest
◦	$125 Million for Socially Responsible Direct Cancer Funding
◦	Advaxis Added To Cancer Immunotherapy Index
◦	MNTR In Discussion With Breast Cancer Immunotherapy Company
◦	Nobel Laureate Reinforces the Mentor Capital Strategy to Fund Only Leading-edge Cancer Science
◦	Mentor Capital to Expand Funding Bridge Over Cancer Development Gap
◦	Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval
◦	MNTR Sees Shift To Public Acceptance
◦	Cancer Index at New High with 12 Yr Exclusive Period in Health Bill
◦	Provectus Pharmaceuticals (PVCT) added to Cancer Immunotherapy Index
◦	MNTR Invests in 10 Cancer Index Companies
◦	MNTR Retains Investment Bank to Assist Roll Out Cancer Immunotherapy Index Fund
◦	2010 Actively Managed Cancer Immunotherapy Index Announced by MNTR
◦	MNTR Presents in NYC
◦	QI Announces MNTR
◦	MNTR Calls $3 Million Tranche
◦	MNTR Initiates Trading

Cancer Resources

Information For Brokers

Shareholder Updates

FAQ

Safe Harbor Statement Site Map